ReviewAntioxidants (Basel, Switzerland)2026
Pathophysiological Roles of Oxidative Stress and the Translational Potential of Antioxidant Therapy in Retinal Vein Occlusion.
Review in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal vein occlusion (RVO) is the second most common retinal vascular disorder after diabetic retinopathy and represents a major cause of visual impairment worldwide. In addition to venous congestion, endothelial dysfunction, and inflammation, accumulating evidence indicates that oxidative stress plays a pivotal role in the pathogenesis of RVO. The excessive production of reactive oxygen species (ROS) during ischemia-reperfusion injury induces endothelial damage, disruption of the blood-retinal barrier, and upregulation of inflammatory cytokines and vascular endothelial growth factor (VEGF), thereby contributing to macular edema and progressive visual dysfunction. This review summarizes current knowledge from both experimental and clinical studies regarding the mechanisms of oxidative stress generation in RVO and its underlying molecular pathways, highlighting the pathological consequences of impaired antioxidant defense systems. We further review reported alterations in oxidative stress markers and antioxidant factors in serum, aqueous humor, and vitreous fluid, and discuss their potential associations with disease activity and visual prognosis. In addition, the interplay between oxidative stress and current standard treatments, including anti-VEGF therapy and corticosteroids, is discussed, together with the translational potential of antioxidant strategies such as polyphenols, vitamins, and Nrf2 pathway activators. At the same time, we address critical challenges limiting clinical application, including insufficient interventional evidence, the lack of validated biomarkers, and uncertainties regarding optimal timing of antioxidant intervention. By providing a comprehensive overview of oxidative stress in RVO, this review aims to identify emerging therapeutic targets and opportunities for personalized treatment approaches, and to outline future research directions toward improving long-term visual outcomes in patients with RVO.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.